Prevention and treatment of type 2 diabetes: Current role of lifestyle, natural product, and pharmacological interventions

被引:89
作者
Hays, Nicholas P. [5 ]
Galassetti, Pietro R. [2 ,3 ,4 ]
Coker, Robert H. [1 ]
机构
[1] Univ Arkansas Med Sci, DWR Inst Aging, Nutr Metab & Exercise Lab, Dept Geriatr, Little Rock, AR 72205 USA
[2] Univ Calif Irvine, Dept Pediat, Irvine, CA 92717 USA
[3] Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA
[4] Univ Calif Irvine, Gen Clin Res Ctr, Irvine, CA 92717 USA
[5] Univ Arkansas Med Sci, Dept Nutr, Little Rock, AR 72205 USA
关键词
insulin resistance; obesity; exercise; nutrition;
D O I
10.1016/j.pharmthera.2008.02.003
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Common complications of type 2 diabetes (T2D) are eye, kidney and nerve diseases, as well as an increased risk for the development of cardiovascular disease and cancer. The overwhelming influence of these conditions contributes to a decreased quality of life and life span, as well as significant economic consequences. Although obesity once served as a surrogate marker for the risk of T2D, we know now that excess adipose tissue secretes inflammatory cytokines that left unchecked, accelerate the progression to insulin resistance and T2D. In addition, excess alcohol consumption may also increase the risk of T2D. From a therapeutic standpoint, lifestyle interventions such as dietary modification and/or exercise training have been shown to improve glucose homeostasis but may not normalize the disease process unless weight loss is achieved and increased physical activity patterns are established. Furthermore, utilization of natural products may serve as a significant adjunct in the fight against insulin resistance but further research is needed to ascertain their validity. Since it is clear that pharmaceutical therapy plays a significant role in the treatment of insulin resistance, this review will also discuss some of the newly developed pharmaceutical therapies that may work in conjunction with lifestyle interventions, and lessen the burden of behavioral change as the only strategy against the development of T2D. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:181 / 191
页数:11
相关论文
共 176 条
[1]
RELATIONSHIPS OF GENERALIZED AND REGIONAL ADIPOSITY TO INSULIN SENSITIVITY IN MEN [J].
ABATE, N ;
GARG, A ;
PESHOCK, RM ;
STRAYGUNDERSEN, J ;
GRUNDY, SM .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (01) :88-98
[2]
Glucose and insulin responses to dietary chromium supplements: a meta-analysis [J].
Althuis, MD ;
Jordan, NE ;
Ludington, EA ;
Wittes, JT .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2002, 76 (01) :148-155
[3]
Liver adenosine monophosphate-activated kinase-α2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin [J].
Andreelli, F ;
Foretz, M ;
Knauf, C ;
Cani, PD ;
Perrin, C ;
Iglesias, MA ;
Pillot, B ;
Bado, A ;
Tronche, F ;
Mithieux, G ;
Vaulont, S ;
Burcelin, R ;
Viollet, B .
ENDOCRINOLOGY, 2006, 147 (05) :2432-2441
[4]
[Anonymous], 2002, CLIN DIABETES
[5]
Insulin resistance in type 2 diabetes: role of fatty acids [J].
Arner, P .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2002, 18 :S5-S9
[6]
ARONNE L, 2007, J CLIN ENDOCR METAB, V293, pE172
[7]
*ASS A D, 2003, J AM DIET ASSOC, V103, P1363
[8]
*ASS A D, 2004, DIABETES CARE, V27, pS135
[9]
Effects of metformin in patients with poorly controlled insulin-treated type 2 diabetes mellitus -: A randomized, double-blind, placebo-controlled trial [J].
Avilés-Santa, L ;
Sinding, J ;
Raskin, P .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (03) :182-+
[10]
Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus [J].
Bajaj, M. ;
Suraamornkul, S. ;
Hardies, L. J. ;
Glass, L. ;
Musi, N. ;
DeFronzo, R. A. .
DIABETOLOGIA, 2007, 50 (08) :1723-1731